Johnson & Johnson (NYSE:JNJ) Stock Holdings Lifted by XML Financial LLC

XML Financial LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 0.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 69,537 shares of the company’s stock after buying an additional 420 shares during the period. Johnson & Johnson accounts for 0.9% of XML Financial LLC’s portfolio, making the stock its 27th largest holding. XML Financial LLC’s holdings in Johnson & Johnson were worth $10,057,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Fred Alger Management LLC lifted its holdings in Johnson & Johnson by 6.1% during the 2nd quarter. Fred Alger Management LLC now owns 42,968 shares of the company’s stock worth $6,280,000 after buying an additional 2,488 shares in the last quarter. Dark Forest Capital Management LP acquired a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $223,000. MBB Public Markets I LLC lifted its stake in Johnson & Johnson by 1,827.5% in the 2nd quarter. MBB Public Markets I LLC now owns 181,395 shares of the company’s stock valued at $26,513,000 after acquiring an additional 171,984 shares in the last quarter. Marathon Capital Management boosted its holdings in Johnson & Johnson by 3.3% during the second quarter. Marathon Capital Management now owns 29,668 shares of the company’s stock worth $4,336,000 after purchasing an additional 940 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Johnson & Johnson by 0.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,686,122 shares of the company’s stock worth $392,603,000 after purchasing an additional 7,107 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on JNJ. Raymond James cut their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Citigroup decreased their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Bank of America decreased their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday. Finally, Stifel Nicolaus dropped their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $170.06.

Johnson & Johnson Stock Up 0.1 %

Shares of NYSE JNJ opened at $146.76 on Friday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The stock has a market cap of $353.34 billion, a P/E ratio of 22.07, a PEG ratio of 2.45 and a beta of 0.51. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The business’s fifty day simple moving average is $147.99 and its 200-day simple moving average is $155.98.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22,438,500 billion. During the same period last year, the business posted $2.29 EPS. The company’s revenue was up 5.3% on a year-over-year basis. As a group, equities analysts predict that Johnson & Johnson will post 10.56 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.38%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.